RxDoctor Payments Data

Timothy Mark, MD

Internal Medicine · West Palm Beach, FLNPI 1588725006

Payments from drug & device makers

$7,182in general payments, 2019–2025

Across 412 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$963
  • Amgen$796
  • Lilly USA, LLC$766
  • AbbVie$417
  • AstraZeneca$395
  • Exact Sciences$284
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,10799%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,182 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$815,346
Medicare patients
542
Services billed
20,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide198$244,065
EliquisApixaban123$133,932
OzempicSemaglutide81$89,835
JardianceEmpagliflozin49$42,765
MyrbetriqMirabegron52$39,437
Repatha SureclickEvolocumab29$24,182
XareltoRivaroxaban18$21,206
ProliaDenosumab12$20,979
GemtesaVibegron27$20,309
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,935
LivaloPitavastatin Calcium11$10,130
SynthroidLevothyroxine Sodium115$8,581
Rivastigmine29$7,719
Rosuvastatin Calcium427$7,109
Breo ElliptaFluticasone/Vilanterol14$6,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$766$244,065198 claims
PfizerEliquis, Paxlovid$963$138,220211 claims
Novo NordiskOzempic$232$89,83581 claims
Boehringer IngelheimJardiance$34$42,76549 claims
Astellas Pharma US IncMyrbetriq$113$39,43752 claims
GSKTrelegy Ellipta, Breo Ellipta$251$22,40129 claims
Johnson & JohnsonXarelto$221$21,20618 claims
AmgenProlia$796$20,97912 claims
Sumitomo Pharma America, Inc.Gemtesa$223$20,30927 claims
Kowa Pharmaceuticals America, Inc.Livalo$147$10,13011 claims
AbbVieSynthroid$417$8,581115 claims
MerckLagevrio (Eua)$234$4,86011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →